RESEARCH NEWS 2019-09-13 Research News Marking the fall of the only remaining BACE inhibitor currently being tested for AD, Biogen and Eisai announced today the discontinuation of two Phase 3 studies of elenbecestat in people with mild cognitive impairment and mild AD. The compa
PAPER Fleming SM, Salcedo J, Hutson CB, Rockenstein E, Masliah E, Levine MS, Chesselet MF
Neuroscience. 2006 Nov 3;142(4):1245-53. Epub 2006 Aug 23 PubMed: 16934409
PAPER Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF
J Neurosci. 2004 Oct 20;24(42):9434-40. PubMed: 15496679
RESEARCH NEWS 2019-09-13 Research News In a second Phase 2 strikeout, the small-molecule drug ladostigil missed its primary endpoint of curbing progression from mild cognitive impairment to AD, though people on a low-dose regimen did have less brain shrinkage over three years tha
PAPER Weinstock M, Bejar C, Schorer-Apelbaum D, Panarsky R, Luques L, Shoham S
J Neuroimmune Pharmacol. 2013 Mar;8(1):345-55. Epub 2013 Jan 17 PubMed: 23325108
RESEARCH NEWS 2019-09-13 Research News The humble locus coeruleus, a minute speck of tissue nestled deep in the brain stem, has received relatively scant attention in studies of cognitive decline. Now, data published September 9 in Nature Human Behavior add to a recent spate of f
PAPER Dahl MJ, Mather M, Düzel S, Bodammer NC, Lindenberger U, Kühn S, Werkle-Bergner M
Nat Hum Behav. 2019 Sep 9; PubMed: 31501542
PAPER Gerstorf D, Bertram L, Lindenberger U, Pawelec G, Demuth I, Steinhagen-Thiessen E, Wagner GG
Gerontology. 2016;62(3):311-5. Epub 2016 Jan 29 PubMed: 26820471
PAPER Manaye KF, McIntire DD, Mann DM, German DC
J Comp Neurol. 1995 Jul 17;358(1):79-87. PubMed: 7560278